Abrocitinib ni umunwa, molekile nto, Janus kinase (JAK) 1 inhibitor mugutezimbere kuvura abantu bakuru ningimbi bafite dermatite itagereranywa kandi ikabije.

Abrocitinib iri gukurikiranwa mu igeragezwa ry’amavuriro NCT03796676 (JAK1 Inhibitor hamwe nubuvuzi bwa Topical Therapy ku rubyiruka rufite Atopic Dermatitis).

Kuri ubu Abrocitinib irimo gutegurwa na Pfizer kugirango ivure atopic dermatitis (eczema). Numunwa wiperereza rimwe kumunsi Janus kinase 1 (JAK1) inhibitor.

Atopic dermatitis (AD) ni indwara igoye, idakira, yanduza uruhu irangwa no kurwara pruritis, kwandura cyane, no gukomeretsa eczematous yibasira abana bagera kuri 25% na 2% kugeza kuri 3% byabantu bakuru ku isi. Abrocitinib ni intiti ihitamo ya enzyme ya Janus kinase-1 (JAK1) ibuza inzira yo gutwika. Kubwibyo, twari tugamije gusuzuma imikorere numutekano bya abrocitinib kuri AD igereranije-ikomeye.

Abrocitinib muri dose 100 mg cyangwa 200 mg ni imiti ikora neza, yihanganira neza, kandi itanga ikizere mu kuvura abarwayi bafite dermatite ya Atopic yoroheje kandi ikabije. Nyamara, isesengura ryashimangiye imikorere ya abrocitinib 200 mg hejuru ya mg 100, ariko ingaruka mbi nko kugira isesemi no kubabara umutwe zishobora kugaragara cyane hamwe na mg 200.